Holen Sie sich die Stockscreener-App
37.22
0.83%
-0.31
Schlusskurs vom Vortag:
$37.53
Offen:
$37.53
24-Stunden-Volumen:
1.98M
Relative Volume:
0.89
Marktkapitalisierung:
$6.93B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-567.06M
KGV:
-10.17
EPS:
-3.66
Netto-Cashflow:
$-551.11M
1W Leistung:
-4.69%
1M Leistung:
-7.02%
6M Leistung:
-9.20%
1J Leistung:
-19.96%
1-Tages-Spanne:
$37.16
$37.80
1-Wochen-Bereich:
$37.16
$39.62
52-Wochen-Spanne:
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
415-766-3638
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Vergleichen Sie RVMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
37.22 | 6.99B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
What analysts say about Revolution Medicines Inc. Equity Warrant stockFastest-growing stock picks - PrintWeekIndia
Revolution Medicines publishes research on RAS G12D inhibitor - Investing.com
What analysts say about Revolution Medicines Inc. stockAccelerated profit realization - PrintWeekIndia
Revolution Medicines Inc. Equity Warrant Stock Analysis and ForecastHigh-octane financial growth - Autocar Professional
What drives Revolution Medicines Inc. stock priceBreakthrough stock performance - Autocar Professional
Is Revolution Medicines Inc. a good long term investmentMarket-leading capital gains - Autocar Professional
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor - GlobeNewswire
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses - MSN
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs - MSN
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib - GlobeNewswire
Revolution Medicines Inc. Stock Analysis and ForecastConsistent wealth multiplication - jammulinksnews.com
Castle Bio, Revolution Medicines get FDA breakthrough statuses - Seeking Alpha
FDA grants breakthrough therapy designation to Revolution Medicines’ lung cancer drug - Investing.com Canada
How will RVMD's EPS trend in Q1 2025? - AInvest
What drives Revolution Medicines Inc. Equity Warrant stock pricePhenomenal trading returns - jammulinksnews.com
Is Revolution Medicines Inc. Equity Warrant a good long term investmentSky-high profits - Autocar Professional
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.32%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):